Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 5, Issue 5 (2016)

Interrelation of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells

Author(s):
Dr. DN Tibarewala, Dr. Sukumar Roy, Dr. Partha Majumder
Abstract:
Cyclooxygenase 2(COX 2) Selective COX-2 inhibitors are a type of non-steroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration, and is the main feature of celecoxib, rofecoxib and other members of this drug class. After several COX-2 inhibiting drugs were approved for marketing, data from clinical trials revealed that COX-2 inhibitors caused a significant increase in heart attacks and strokes, with some drugs in the class having worse risks than others. Rofecoxib (commonly known as Vioxx) was taken off the market in 2004 because of these concerns and celecoxib and traditional NSAIDs received boxed warnings on their labels
Pages: 21-27  |  726 Views  14 Downloads
How to cite this article:
Dr. DN Tibarewala, Dr. Sukumar Roy, Dr. Partha Majumder. Interrelation of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. 2016; 5(5): 21-27.
Journals List Click Here Research Journals Research Journals
Call for book chapter